Non-drug costs associated with outpatient infliximab administration in pediatric inflammatory bowel disease.
about
Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitisImplementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel diseaseLow dose thiopurine and allopurinol co-therapy results in significant cost savings at a district general hospital.Frequency of Severe Infusion Reactions Associated With Outpatient Infusion of Infliximab Without Premedications.Changing face of care for patients with moderate to severe inflammatory bowel disease: the role of specialist nurses in the governance of anti-TNF prescribing.
P2860
Non-drug costs associated with outpatient infliximab administration in pediatric inflammatory bowel disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Non-drug costs associated with ...... ic inflammatory bowel disease.
@en
type
label
Non-drug costs associated with ...... ic inflammatory bowel disease.
@en
prefLabel
Non-drug costs associated with ...... ic inflammatory bowel disease.
@en
P2093
P2860
P1476
Non-drug costs associated with ...... ic inflammatory bowel disease.
@en
P2093
P2860
P304
P356
10.1097/MIB.0B013E318281F4F1
P577
2013-06-01T00:00:00Z